


**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
PG3654USw

In Re Application Of:  
ANDERSON, et. al.



Serial No.  
09/937,232

Filing Date  
09/24/2002

PATENT & TRADEMARK OFFICE Examiner  
CARTAGENA

Group Art Unit  
3754

Title:  
**VALVE**

**RECEIVED**

AUG - 8 2002

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:


TECHNOLOGY CENTER R3700

Transmitted herewith is:

**Amendment Transmittal Letter with Amendment  
Supplemental Information Disclosure Statement with Form PTO-1449 and References  
Petition to Accept an Unintentionally Delayed Priority Claim Under 37 C.F.R. 1.78 (Copy)  
Associate Power of Attorney or Agent**

in the above identified application.

- No additional fee is required.
- A check in the amount of \_\_\_\_\_ is attached.
- The Commissioner is hereby authorized to charge and credit Deposit Account No. 07-1392 as described below. A duplicate copy of this sheet is enclosed.
- Charge the amount of \_\_\_\_\_
- Credit any overpayment.
- Charge any additional fee required.



Signature

Robert J. Smith  
Reg. No.: 40,820  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709  
Telephone: 919-483-9616 / Facsimile: 919-483-7988




23347

PATENT TRADEMARK OFFICE

CC:

I certify that this document and fee is being deposited on 7-30-02 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Ban Younan

Typed or Printed Name of Person Mailing Correspondence

0370-3754  
DT062 E'd PCT/PTO 05 AUG 2002

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Applicant(s): ANDERSON, et. al.

Docket No.

PG3654USw

Serial No.  
09/937,232

Filing Date  
09/24/2001

Examiner  
CARTAGENA

Group Art Unit  
3754

Invention:  
VALVE



RECEIVED  
3754

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

AUG - 8 2002

TECHNOLOGY CENTER R3700

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	31 -	30 =	1	x \$18.00	\$18.00
INDEP. CLAIMS	1 -	3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable)					\$0.00
					TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$18.00

RECEIVED

FEB 10 2003

TECHNOLOGY CENTER R3700

- No additional fee is required for amendment.  
 Please charge Deposit Account No. 07-1392 in the amount of \$18.00  
A duplicate copy of this sheet is enclosed.  
 A check in the amount of to cover the filing fee is enclosed.  
 The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392  
A duplicate copy of this sheet is enclosed.  
 Any additional filing fees required under 37 C.F.R. 1.16.  
 Any patent application processing fees under 37 CFR 1.17.

Signature

Dated:

Robert J. Smith  
Reg. No.: 40,820  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
PO Box 13398  
Research Triangle Park, NC 27709  
Telephone: 919-483-9616 / Facsimile: 919-483-7988



23347

PATENT TRADEMARK OFFICE

CC:

I certify that this document and fee is being deposited on 7-30-02 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence